| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Isoxanthohumol targets multiple pathways involved in inflammation, angiogenesis, and cell proliferation. It induces apoptosis in mature adipocytes and inhibits the differentiation of preadipocytes. It also shows antiviral activity against herpes viruses (HSV1 and HSV2) and bovine viral diarrhea virus (BVDV).
|
|---|---|
| ln Vitro |
In vitro, Isoxanthohumol exhibits antiproliferative activity against human breast cancer (MDA-MB-231, T-47D, MCF-7), ovarian cancer (A-2780), prostate cancer, and colon cancer (HT-29, SW620) cell lines. It shows antiviral activity against HSV1, HSV2, and BVDV. It induces apoptosis in mature adipocytes and inhibits preadipocyte differentiation.
|
| ln Vivo |
In vivo, Isoxanthohumol seems to regulate vascular proliferation and stabilization. It has been studied in models of key stages of colon tumorigenesis. It has weakly estrogenic activity.
|
| Enzyme Assay |
In vitro enzyme assays for Isoxanthohumol are not widely detailed. Its antioxidant activity can be assessed using cell-free systems like DPPH or ABTS radical scavenging assays. Its anti-inflammatory activity can be studied by measuring its ability to inhibit COX-2 or other inflammatory enzymes.
|
| Cell Assay |
In vitro cellular assays for Isoxanthohumol are performed on various cancer cell lines to assess its antiproliferative effects. Cells are treated with the compound for 48-72 hours, and cell viability is measured using MTT or SRB assays. Apoptosis is assessed by annexin V staining and caspase-3/7 activity. Its anti-angiogenic activity is studied using endothelial cell tube formation assays.
|
| Animal Protocol |
In vivo animal studies for Isoxanthohumol are conducted in mouse models of cancer, such as xenograft models using breast or colon cancer cell lines. The compound is administered orally or intraperitoneally, and tumor growth is measured. Its effect on vascular proliferation and stabilization is assessed by immunohistochemistry of tumor tissue.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Isoxanthohumol are limited. It can be converted to the more strongly estrogenic 8-prenylnaringenin by the colonic microbiota. This biotransformation is important for its biological effects. Its oral bioavailability and metabolism are subjects of ongoing research.
|
| Toxicity/Toxicokinetics |
Toxicological data for Isoxanthohumol are not widely published. As a natural compound found in hops and beer, it has a history of human consumption. No significant toxicity has been reported in the available literature at the doses used in studies.
|
| References | |
| Additional Infomation |
Reports indicate that hops and sophora flavescens contain (2S)-isoxanthohumol, and relevant data are available for reference.
Isoxanthohumol is a natural flavonoid found in hops and other plants. It is studied for its potential anticancer, anti-inflammatory, and antiviral activities. It is not an approved drug but is used as a research compound to study its various biological properties. |
| Molecular Formula |
C21H22O5
|
|---|---|
| Molecular Weight |
354.4
|
| Exact Mass |
354.146
|
| Elemental Analysis |
C, 71.17; H, 6.26; O, 22.57
|
| CAS # |
70872-29-6
|
| Related CAS # |
Isoxanthohumol; 521-48-2
|
| PubChem CID |
9928523
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
585.8±50.0 °C at 760 mmHg
|
| Melting Point |
196-208℃
|
| Flash Point |
208.6±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
5.07
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
519
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2=C(C(=C([H])C(=C2C(C([H])([H])C1([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)OC([H])([H])[H])O[H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H]
|
| InChi Key |
YKGCBLWILMDSAV-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C21H22O5/c1-12(2)4-9-15-16(23)10-19(25-3)20-17(24)11-18(26-21(15)20)13-5-7-14(22)8-6-13/h4-8,10,18,22-23H,9,11H2,1-3H3/t18-/m0/s1
|
| Chemical Name |
(2S)-7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
| Synonyms |
Isoxanthohumol; (2S)-4',7-Dihydroxy-5-methoxy-8-prenylflavanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
